524711 — Vista Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹636.41m
- IN₹726.55m
- IN₹10.04m
- 25
- 12
- 47
- 13
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 311 | 228 | 12.7 | 3.95 | 10 |
Cost of Revenue | |||||
Gross Profit | 56.6 | -11.8 | 5.36 | 0.28 | -18.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 312 | 289 | 37.2 | 22.2 | 60.7 |
Operating Profit | -1.27 | -61.4 | -24.6 | -18.3 | -50.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 11.5 | -39.4 | -36.9 | -25.6 | -58.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 9.39 | -36.8 | -18.9 | -8.32 | -56.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 9.39 | -36.8 | -18.9 | -8.32 | -56.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 9.39 | -36.8 | -18.9 | -8.32 | -56.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.304 | -1.21 | -0.544 | -0.226 | -1.54 |